Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes



Status:Terminated
Conditions:Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - 65
Updated:11/2/2018
Start Date:February 2001
End Date:May 2005

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy

Objectives:

1. Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute
leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell
transplants.

2. Quantitate the alloreactivity of DC/ADL and circulating immune effector cells in
patients after infusion.

3. Assess efficacy of acute myelogenous leukemia (AML) or Chronic Myelogenous Leukemia in
Blastic Crisis (CML-BC) derived dendritic cells and activated lymphocytes in promoting
and sustaining remission in patients with relapse after allo-BMT or stem cell
transplant.


Inclusion Criteria:

- AML (any type except M3) or CIVIL in blast crisis with greater than or equal to 20%
bone marrow blasts at the time of related donor marrow or stem cell transplantation or
at relapse post transplant.

- Willing to undergo a skin biopsy and either a leukodepletion apheresis or an
additional marrow aspiration.

- Stem cell or marrow donor willing to have apheresis for T-Cell collection.

- Written voluntary informed consent must be obtained from patient and donor.

Exclusion Criteria:

- Medical, social or psychologic factors which would prevent the patient from receiving
or cooperating with the full course of therapy or understanding the informed consent
procedure.

- AML French-American-British (FAB) subtype M3.
We found this trial at
1
site
M.D. Anderson Cancer Center
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials